{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:48:49Z","timestamp":1761976129489,"version":"build-2065373602"},"reference-count":30,"publisher":"Pharmaceutical Society of Japan","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,11,1]]},"DOI":"10.1248\/bpb.b25-00229","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:08:17Z","timestamp":1761948497000},"page":"1687-1693","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of Experimental Autoimmune Encephalomyelitis with Lipid Nanoparticles Loaded with siRNA Targeting Neogenin"],"prefix":"10.1248","volume":"48","author":[{"given":"Kosuke","family":"Shimizu","sequence":"first","affiliation":[{"name":"Nanotheranostics Laboratory, Division of Innovative Diagnostic and Therapeutic Research, Institute of Photonics Medicine, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) DeLuca J, Chiaravalloti ND, Sandroff BM. Treatment and management of cognitive dysfunction in patients with multiple sclerosis. <i>Nat. Rev. Neurol.<\/i>, <b>16<\/b>, 319\u2013332 (2020).","DOI":"10.1038\/s41582-020-0355-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Oshima Y, Tanimoto T, Yuji K, Tojo A. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. <i>Mult. Scler.<\/i>, <b>25<\/b>, 1141\u20131149 (2019).","DOI":"10.1177\/1352458518786075"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) De Vries M, Cooper HM. Emerging roles for neogenin and its ligands in CNS development. <i>J. Neurochem.<\/i>, <b>106<\/b>, 1483\u20131492 (2008).","DOI":"10.1111\/j.1471-4159.2008.05485.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Matsunaga E, Tauszig-Delamasure S, Monnier PP, Mueller BK, Strittmatter SM, Mehlen P, Ch\u00e9dotal A. RGM and its receptor neogenin regulate neuronal survival. <i>Nat. Cell Biol.<\/i>, <b>6<\/b>, 749\u2013755 (2004).","DOI":"10.1038\/ncb1157"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Lee NK, Fok KW, White A, Wilson NH, O\u2019Leary CJ, Cox HL, Michael M, Yap AS, Cooper HM. Neogenin recruitment of the WAVE regulatory complex maintains adherens junction stability and tension. <i>Nat. Commun.<\/i>, <b>7<\/b>, 11082 (2016).","DOI":"10.1038\/ncomms11082"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Boneschansker L, Nakayama H, Eisenga M, Wedel J, Klagsbrun M, Irimia D, Briscoe DM. Netrin-1 augments chemokinesis in CD4<sup>+<\/sup> T cells <i>in vitro<\/i> and elicits a proinflammatory response <i>in vivo.<\/i> <i>J. Immunol.<\/i>, <b>197<\/b>, 1389\u20131398 (2016).","DOI":"10.4049\/jimmunol.1502432"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Muramatsu R, Kubo T, Mori M, Nakamura Y, Fujita Y, Akutsu T, Okuno T, Taniguchi J, Kumanogoh A, Yoshida M, Mochizuki H, Kuwabara S, Yamashita T. RGMa modulates T cell responses and is involved in autoimmune encephalomyelitis. <i>Nat. Med.<\/i>, <b>17<\/b>, 488\u2013494 (2011).","DOI":"10.1038\/nm.2321"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Tanabe S, Yamashita T. Repulsive guidance molecule-a is involved in Th17-cell-induced neurodegeneration in autoimmune encephalomyelitis. <i>Cell Rep.<\/i>, <b>9<\/b>, 1459\u20131470 (2014).","DOI":"10.1016\/j.celrep.2014.10.038"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Asai T, Matsushita S, Kenjo E, Tsuzuku T, Yonenaga N, Koide H, Hatanaka K, Dewa T, Nango M, Maeda N, Kikuchi H, Oku N. Dicetyl phosphate-tetraethylenepentamine-based liposomes for systemic siRNA delivery. <i>Bioconjug. Chem.<\/i>, <b>22<\/b>, 429\u2013435 (2011).","DOI":"10.1021\/bc1004697"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Belliveau NM, Huft J, Lin PJ, Chen S, Leung AK, Leaver TJ, Wild AW, Lee JB, Taylor RJ, Tam YK, Hansen CL, Cullis PR. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for <i>in vivo<\/i> delivery of siRNA. <i>Mol. Ther. Nucleic Acids<\/i>, <b>1<\/b>, e37 (2012).","DOI":"10.1038\/mtna.2012.28"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Goverman J. Autoimmune T cell responses in the central nervous system. <i>Nat. Rev. Immunol.<\/i>, <b>9<\/b>, 393\u2013407 (2009).","DOI":"10.1038\/nri2550"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Wang D, Ghosh D, Islam SM, Moorman CD, Thomason AE, Wilkinson DS, Mannie MD. IFN-\u03b2 facilitates neuroantigen-dependent induction of CD25<sup>+<\/sup> FOXP3<sup>+<\/sup> regulatory T cells that suppress experimental autoimmune encephalomyelitis. <i>J. Immunol.<\/i>, <b>197<\/b>, 2992\u20133007 (2016).","DOI":"10.4049\/jimmunol.1500411"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, Chun J. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>108<\/b>, 751\u2013756 (2011).","DOI":"10.1073\/pnas.1014154108"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Putzki N, Baranwal MK, Tettenborn B, Limmroth V, Kreuzfelder E. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. <i>Eur. Neurol.<\/i>, <b>63<\/b>, 311\u2013317 (2010).","DOI":"10.1159\/000302687"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Skarica M, Eckstein C, Whartenby KA, Calabresi PA. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. <i>J. Neuroimmunol.<\/i>, <b>235<\/b>, 70\u201376 (2011).","DOI":"10.1016\/j.jneuroim.2011.02.010"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Major EO, Yousry TA, Clifford DB. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. <i>Lancet Neurol.<\/i>, <b>17<\/b>, 467\u2013480 (2018).","DOI":"10.1016\/S1474-4422(18)30040-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Niimi N, Kohyama K, Matsumoto Y. Therapeutic gene silencing with siRNA for IL-23 but not for IL-17 suppresses the development of experimental autoimmune encephalomyelitis in rats. <i>J. Neuroimmunol.<\/i>, <b>254<\/b>, 39\u201345 (2013).","DOI":"10.1016\/j.jneuroim.2012.08.015"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Wang X, Zheng X, Ma C, Zhao L. Role of TRIF small interference RNA (siRNA) in chronic experimental allergic encephalomyelitis (EAE). <i>Med. Sci. Monit.<\/i>, <b>21<\/b>, 2583\u20132587 (2015).","DOI":"10.12659\/MSM.894564"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Yang Y, Liu Y, Wei P, Peng H, Winger R, Hussain RZ, Ben L, Cravens PD, Gocke AR, Puttaparthi K, Racke MK, McTigue DM, Lovett-Racke AE. Silencing Nogo-A promotes functional recovery in demyelinating disease. <i>Ann. Neurol.<\/i>, <b>67<\/b>, 498\u2013507 (2010).","DOI":"10.1002\/ana.21935"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Yan Y, Ding X, Li K, Ciric B, Wu S, Xu H, Gran B, Rostami A, Zhang G. CNS-specific therapy for ongoing EAE by silencing IL-17 pathway in astrocytes. <i>Mol. Ther.<\/i>, <b>20<\/b>, 1338\u20131348 (2012).","DOI":"10.1038\/mt.2012.12"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Zhang R, Tian A, Wang J, Shen X, Qi G, Tang Y. miR26a modulates Th17\/T reg balance in the EAE model of multiple sclerosis by targeting IL6. <i>Neuromolecular Med.<\/i>, <b>17<\/b>, 24\u201334 (2015).","DOI":"10.1007\/s12017-014-8335-5"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Guan H, Fan D, Mrelashvili D, Hao H, Singh NP, Singh UP, Nagarkatti PS, Nagarkatti M. MicroRNA let-7e is associated with the pathogenesis of experimental autoimmune encephalomyelitis. <i>Eur. J. Immunol.<\/i>, <b>43<\/b>, 104\u2013114 (2013).","DOI":"10.1002\/eji.201242702"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Doi Y, Oki S, Ozawa T, Hohjoh H, Miyake S, Yamamura T. Orphan nuclear receptor NR4A2 expressed in T cells from multiple sclerosis mediates production of inflammatory cytokines. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>105<\/b>, 8381\u20138386 (2008).","DOI":"10.1073\/pnas.0803454105"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Yang Y, Weiner J, Liu Y, Smith AJ, Huss DJ, Winger R, Peng H, Cravens PD, Racke MK, Lovett-Racke AE. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. <i>J. Exp. Med.<\/i>, <b>206<\/b>, 1549\u20131564 (2009).","DOI":"10.1084\/jem.20082584"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Hatanaka K, Asai T, Koide H, Kenjo E, Tsuzuku T, Harada N, Tsukada H, Oku N. Development of double-stranded siRNA labeling method using positron emitter and its <i>in vivo<\/i> trafficking analyzed by positron emission tomography. <i>Bioconjug. Chem.<\/i>, <b>21<\/b>, 756\u2013763 (2010).","DOI":"10.1021\/bc9005267"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. <i>Mol. Ther.<\/i>, <b>25<\/b>, 1467\u20131475 (2017).","DOI":"10.1016\/j.ymthe.2017.03.013"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Cullis PR, Felgner PL. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. <i>Nat. Rev. Drug Discov.<\/i>, <b>23<\/b>, 709\u2013722 (2024).","DOI":"10.1038\/s41573-024-00977-6"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Kimura S, Harashima H. On the mechanism of tissue-selective gene delivery by lipid nanoparticles. <i>J. Control. Release<\/i>, <b>362<\/b>, 797\u2013811 (2023).","DOI":"10.1016\/j.jconrel.2023.03.052"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Kheirolomoom A, Kare AJ, Ingham ES, Paulmurugan R, Robinson ER, Baikoghli M, Inayathullah M, Seo JW, Wang J, Fite BZ, Wu B, Tumbale SK, Raie MN, Cheng RH, Nichols L, Borowsky AD, Ferrara KW. <i>In situ<\/i> T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift. <i>Biomaterials<\/i>, <b>281<\/b>, 121339 (2022).","DOI":"10.1016\/j.biomaterials.2021.121339"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Thatte AS, Hamilton AG, Nachod BE, Mukalel AJ, Billingsley MM, Palanki R, Swingle KL, Mitchell MJ. mRNA lipid nanoparticles for <i>ex vivo<\/i> engineering of immunosuppressive T cells for autoimmunity therapies. <i>Nano Lett.<\/i>, <b>23<\/b>, 10179\u201310188 (2023).","DOI":"10.1021\/acs.nanolett.3c02573"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/11\/48_b25-00229\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T03:24:17Z","timestamp":1761967457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/11\/48_b25-00229\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00229","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"article-number":"b25-00229"}}